GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 01, 2025, titled "Media release: Q1 of 2025-26".
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
GlaxoSmithKline Pharmaceuticals (GSK India) announced its Q1 FY2025-26 results for the quarter ended June 30, 2025. Revenue from Operations stood at INR 805 crores with a Profit After Tax (PAT) of INR 205 crores, reporting flat growth. The General Medicines portfolio (anti-infectives, pain management, dermatology) saw strong market share gains, though performance was below expectations due to seasonal disruption. The Vaccines business continued strong momentum, led by Shingrix in adult immunisation. The company is preparing to launch its Oncology portfolio, including Jemperli for endometrial cancer and Zejula for ovarian cancer.
Flat quarterly growth combined with below-expected performance may create short-term pressure on sentiment, but the upcoming Oncology portfolio launch and continued strength in Vaccines offer a long-term growth catalyst for shareholders.